Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
Scand J Clin Lab Invest Suppl
; 207: 15-8, 1991.
Article
en En
| MEDLINE
| ID: mdl-1780684
ABSTRACT
The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Inhibidor de Tripsina Pancreática de Kazal
/
Enfermedades de los Genitales Femeninos
/
Neoplasias de los Genitales Femeninos
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Scand J Clin Lab Invest Suppl
Año:
1991
Tipo del documento:
Article
País de afiliación:
Italia